FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through these links, a commission may be earned at no additional cost to you. This article is for informational purposes only and is not medical advice.
If you are researching GLP-1 telehealth programs in 2026, you are probably comparing more than one platform. The problem is that most comparison articles online are written by companies that sell GLP-1 programs or by affiliates who earn commissions from the platform they rank highest. That does not make their information wrong, but it does mean you should look for comparisons where the financial incentive is disclosed and the assessment covers weaknesses alongside strengths.
This comparison uses publicly available pricing, verified review data, disclosed regulatory actions, and published terms of service from each platform. Where information could not be independently verified, it is noted.
MEDVi
What they offer: Compounded semaglutide injections starting at $179 first month ($299 refills), compounded tirzepatide at $349 per month, oral GLP-1 tablets starting at $249. Also now offers branded Wegovy and Zepbound through a $99 membership path. QUAD compounded ED program available as a separate product line.
Clinical model: Asynchronous intake reviewed by OpenLoop Health clinicians. No video visit required in most states. 24/7 messaging access to care team.
Review data: Trustpilot 4.4-4.5 out of 5 across 11,400+ reviews. ConsumerAffairs 3.6 out of 5 across approximately 1,600 reviews. The gap reflects different reviewer demographics — Trustpilot includes invited reviews, ConsumerAffairs attracts more complaint-driven traffic.
Regulatory status: LegitScript certified (active). FDA warning letter February 2026 for GLP-1 marketing practices. Warning letter addressed marketing language, not medication safety. Over 30 other telehealth companies received similar warnings.
Biggest consumer complaint pattern: Auto-renewal billing confusion, 72-hour cancellation notice requirement, and refund terms that surprised some enrollees.
What stands out: Lowest compounded GLP-1 entry price among major platforms. Expanding into branded medications. Also offers the QUAD ED program, which is a separate product line unrelated to the GLP-1 controversy. For the full analysis of MEDVi's regulatory situation, consumer data, and verified facts, see our comprehensive fact-check.
View the current MEDVi program details (official MEDVi page)
Hims & Hers
What they offer: Compounded semaglutide injections and oral formulations. Announced March 2026 collaboration with Novo Nordisk to offer branded Wegovy. Oral compounded semaglutide was briefly launched in February 2026 then withdrawn under regulatory pressure. Pricing varies by formulation.
Clinical model: Established telehealth infrastructure with both asynchronous and synchronous options depending on state. Publicly traded company with over 2,400 employees.
Review data: Trustpilot 3.9 out of 5 across a large review base. Generally more established brand recognition than newer entrants.
Regulatory status: Referred to the Department of Justice by HHS General Counsel in February 2026 for investigation of potential federal law violations related to compounded semaglutide. Sued by Novo Nordisk for patent infringement. Withdrew compounded oral semaglutide product in February 2026.
Biggest consumer complaint pattern: Pricing complexity across multiple product tiers, difficulty distinguishing compounded from branded options on the platform.
What stands out: Largest established brand in the space. Novo Nordisk collaboration signals a pivot toward branded GLP-1 access. Regulatory situation is arguably more serious than MEDVi's given the DOJ referral.
Ro (Roman Health)
What they offer: Both compounded and branded GLP-1 options including Wegovy. Branded Wegovy programs starting around $199 per month for the first two months with promotional pricing. Also offers body composition and metabolic health programs.
Clinical model: More comprehensive clinical intake than many competitors. Offers lab testing integration and ongoing provider check-ins. Positions itself as closer to traditional medical care than pure prescription delivery.
Review data: Generally positive across review platforms. Fewer billing-related complaints compared to some competitors, possibly reflecting more transparent pricing structures.
Regulatory status: No publicly reported FDA warning letters or DOJ referrals as of this writing. Offers FDA-approved branded medications alongside compounded options, with clearer labeling distinguishing the two.
Biggest consumer complaint pattern: Higher pricing than competitors offering compounded-only options. Insurance support available for branded medications but not guaranteed.
What stands out: Best option for consumers who prioritize FDA-approved medications and more hands-on clinical oversight. Higher price reflects a different care model, not just a bigger markup.
Henry Meds
What they offer: Compounded semaglutide starting at $197-$297 per month depending on dosage. Compounded tirzepatide available at higher price points. Focused primarily on compounded formulations.
Clinical model: Telehealth consultation with licensed providers. Straightforward subscription model.
Review data: Smaller review base than MEDVi or Hims. Fewer billing-related complaints relative to customer volume based on publicly available data.
Regulatory status: No publicly reported FDA warning letters or major enforcement actions as of this writing. Lower profile may mean less regulatory attention but also less public verification data available.
Biggest consumer complaint pattern: Limited public complaint data makes assessment less definitive. Some users report dosage availability issues.
What stands out: Competitive compounded pricing with a simpler product lineup. Good option for consumers who want compounded GLP-1 without navigating a complex multi-tier platform.
How to Use This Comparison
No platform in this space is perfect. Every option involves tradeoffs between price, regulatory certainty, clinical oversight, and convenience. The right choice depends on your priorities.
If your top priority is the lowest price for compounded GLP-1 access, MEDVi currently offers the lowest entry point at $179. If your top priority is FDA-approved medication with established clinical evidence, Ro's branded Wegovy path or the Hims/Novo Nordisk collaboration provide that. If your priority is minimal billing complexity, Henry Meds and Ro both have simpler subscription structures.
Regardless of which platform you choose, read the enrollment terms before you pay, understand the cancellation process, and talk with your own doctor before starting any GLP-1 medication. For a practical guide to protecting yourself during enrollment, see our enrollment fine print guide.
Pricing and regulatory information in this comparison reflects publicly available data as of April 2026 and is subject to change. Verify current terms directly with each platform before making enrollment decisions.
This article is for informational purposes only. It is not medical or legal advice. GLP-1 medications require a prescription and clinical evaluation. Compounded medications are not FDA-approved finished products. Consult licensed professionals for medical guidance.
MedicalFoundationOfNC.org Editorial Team | Published April 2026